Sarepta Adds Another Supporter

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

In this video, Motley Fool health-care analyst David Williamson takes a closer look at Sarepta's (NASDAQ: SRPT  ) big move on Friday. Wall Street is starting to wake up to this small biotech story and several key catalysts in the coming months could attract even more attention.


The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 27, 2013, at 9:30 PM, thetruthsquad wrote:

    Your statement that the Cowen report has no price target is incorrect. On page 40 of the report, a "fair value" price target of $55.47 is given. This price target assumes (1) no accelerated approval, (2) no european sales of any kind, and (3) no sales relating to any exons besides exon 51. In my view, this report is the first to adequately explain how the potential upside of the stock is not actually dependent on the outcome of the "accelerated approval" issue. Assuming the science continues to deliver results, this company will be selling exon 51 product in 2016, post a P3. Granted, AA would accelerate this outcome by approximately 18 months, but the inherent value of the company is NOT dependent upon AA. If the science holds, the stock is a screaming buy in the 20s. AA would make it a super screaming buy.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2217145, ~/Articles/ArticleHandler.aspx, 9/27/2016 8:15:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
SRPT $59.66 Up +1.83 +3.16%
Sarepta Therapeuti… CAPS Rating: **
GSK $42.96 Down -0.46 -1.06%
GlaxoSmithKline CAPS Rating: ***